Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Zileuton. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 known ✓ | P09917 | 6/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | PTGES | O14684 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | LTA4H | P09960 | 1/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | ALOX12 | P18054 | 1/20 | 1.00 |
| ▸ | ALOX5AP | P20292 | 1/20 | 1.00 |
| ▸ | LOX | P28300 | 1/20 | 1.00 |
| ▸ | EPHX2 | P34913 | 1/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 1.00 |
| ▸ | LTB4R | Q15722 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zileuton SCHEMBL8876686 | 1.00 | ALOX5 (1.00) | ALOX5CYP1A2PTGESLMNALTA4H | |
| Zileuton SCHEMBL6601944 | 1.00 | ALOX5 (1.00) | ALOX5CYP1A2PTGESLMNALTA4H | |
| Zileuton SCHEMBL4209 | 1.00 | ALOX5 (1.00) | ALOX5CYP1A2PTGESLMNALTA4H | |
| Zileuton SCHEMBL18251470 | 1.00 | ALOX5 (1.00) | ALOX5CYP1A2PTGESLMNALTA4H | |
| Zileuton SCHEMBL28562765 | 0.99 | ALOX5 (0.97) | ALOX5CYP1A2PTGESLMNALTA4H | |
| Zileuton SCHEMBL9602587 | 0.99 | ALOX5 (0.97) | ALOX5CYP1A2PTGESLMNALTA4H | |
| Zileuton SCHEMBL6335013 | 0.99 | ALOX5 (0.97) | ALOX5CYP1A2PTGESLMNALTA4H | |
| Zileuton SCHEMBL20770716 | 0.95 | ALOX5 (0.90) | ALOX5CYP1A2PTGESLMNALTA4H | |
| Methylamine SCHEMBL9601432 | 0.87 | ALOX5 (0.77) | ALOX5CYP1A2PTGESLMNALTA4H | |
| SCHEMBL1444813 | 0.87 | ALOX5 (0.76) | ALOX5CYP1A2PTGESLMNALTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1925 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025151851-A1 | BIOMARKERS OF ALLERGIC ASTHMA AND METHODS OF TREATMENT | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2025-07-17 | — | — | WO | claimed |
| US-20240390364-A1 | Novel Pyridine Compositions and their use in methods for preventing or treating diseases, disorders and conditions | REID CHRISTOPHER BRIAN (US) | 2024-11-28 | — | — | US | claimed |
| WO-2023203306-A1 | COMPOSITIONS AND APPLICATIONS THEREOF | NASALEZE PATENTS LIMITED (IM) | 2023-10-26 | — | — | WO | claimed |
| EP-3044316-B1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS | INST NAT SANTE RECH MED (FR) | 2018-12-26 | — | — | EP | claimed |
| WO-2017161387-A1 | COMPOSITIONS OF NATURAL EXTRACTS AND USE THEREOF IN METHODS FOR PREVENTING OR TREATING DISEASES | REID CHRISTOPHER BRIAN (US) | 2017-09-21 | — | — | WO | claimed |
| US-20170128475-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING ORGAN INJURY AND/OR DYSFUNCTION | THE GENERAL HOSPITAL CORPORATION (US) | 2017-05-11 | — | — | US | claimed |
| CN-106456628-A | Heterocyclic compounds for the treatment of PI 3K-gamma mediated disorders | 无限药品股份有限公司 | 2017-02-22 | — | — | CN | claimed |
| EP-3119397-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF PI3K-GAMMA MEDIATED DISORDERS | Infinity Pharmaceuticals, Inc. (US) | 2017-01-25 | — | — | EP | claimed |
| WO-2016033187-A1 | USE OF GELSOLIN IN THE TREATMENT AND DIAGNOSIS OF SICKLE CELL DISEASE | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2016-03-03 | — | — | WO | claimed |
| US-20160022692-A1 | TREATMENT OF RHEUMATOID ARTHRITIS AND ASTHMA USING PI3 KINASE INHIBITORS | INFINITY PHARMACEUTICALS, INC. | 2016-01-28 | — | — | US | claimed |
| EP-2914295-A1 | TREATMENT OF RHEUMATOID ARTHRITIS AND ASTHMA USING P13 KINASE INHIBITORS | Infinity Pharmaceuticals, Inc. (US) | 2015-09-09 | — | — | EP | claimed |
| US-20140271923-A1 | Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions | REID CHRISTOPHER BRIAN (US) | 2014-09-18 | — | — | US | claimed |
| US-20140148413-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING ORGAN INJURY AND/OR DYSFUNCTION | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2014-05-29 | — | — | US | claimed |
| WO-2014071105-A1 | TREATMENT OF RHEUMATOID ARTHRITIS AND ASTHMA USING P13 KINASE INHIBITORS | INFINITY PHARMACEUTICALS, INC. (US) | 2014-05-08 | — | — | WO | claimed |
| EP-2585109-A2 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING ORGAN INJURY AND/OR DYSFUNCTION | The General Hospital Corporation (US) | 2013-05-01 | — | — | EP | claimed |
| WO-2011163308-A2 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING ORGAN INJURY AND/OR DYSFUNCTION | THE GENERAL HOSPITAL CORPORATION (US) | 2011-12-29 | — | — | WO | claimed |
| US-20090325909-A1 | Suppression of HIV replication and prevention and treatment of HIV | THE JOHNS HOPKINS UNIVERSITY (US) | 2009-12-31 | — | — | US | claimed |
| WO-2007136789-A2 | METHODS OF PREVENTING, TREATING OR AMELIORATING ENHANCED RESPIRATORY DISEASE VIA INNATE IMMUNE MECHANISMS | MEDIMMUNE, INC. (US) | 2007-11-29 | — | — | WO | claimed |
| WO-2005030149-A2 | SUPPRESSION OF HIV REPLICATION FOR PREVENTION AND TREATMENT OF HIV | THE JOHNS HOPKINS UNIVERSITY (US) | 2005-04-07 | — | — | WO | claimed |
| WO-2005021722-A2 | METHODS AND COMPOSITIONS FOR INHIBITION OF NUCLEAR FACTOR κB | THE JOHNS HOPKINS UNIVERSITY (US) | 2005-03-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022692-A1 | TREATMENT OF RHEUMATOID ARTHRITIS AND ASTHMA USING PI3 KINASE INHIBITORS | PIK3CA, PIK3CG, PIK3CD | ALOX5 847/4885CYP1A2 2042/4885PTGES 661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.